FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list

Key Points:

• The FDA's Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, to add the peptide BPC-157 to a drug compounding list, moving it closer to legal availability by prescription in the U.S., though the vote is non-binding and requires FDA approval.
• BPC-157 is popular online for its purported gut and tissue healing benefits, but there is limited human clinical trial data supporting its safety and effectiveness, with most studies conducted on rodents.
• The committee is considering an atypical regulatory pathway that would allow peptides like BPC-157 to be compounded without undergoing full FDA approval, raising concerns about safety and the potential for misleading perceptions of the peptide’s evaluation.
• Supporters of the move believe the risks of BPC-157 are minimal, while opponents worry about safety, effectiveness, and the lack of rigorous FDA evaluation, highlighting ongoing debates within the committee.
• The decision comes amid scrutiny over financial conflicts of interest among newly appointed PCAC members and increased promotion of peptides by public figures, including Health and Human Services Secretary Robert F. Kennedy Jr.